Clinical trialNCT05620771RecruitingPhase 2Interventional

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

SponsorNorthwestern UniversityEnrollment200Hepatocellular Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Aparna Kalyan, MD
Northwestern University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Northwestern University
Chicago, Illinois, United States
Aparna Kalyan, MD
Recruiting
Northwestern Medicine Kishwaukee Hospital
DeKalb, Illinois, United States
Recruiting
Northwestern Medicine Delnor Hospital
Geneva, Illinois, United States
Recruiting
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois, United States
Recruiting
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, United States
Recruiting
Northwestern Medicine Orland Park
Orland Park, Illinois, United States
Recruiting
Northwestern Medicine Warrenville
Warrenville, Illinois, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Y90 + Atezolizumab and BevacizumabY90 + TKI

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2022
Primary completion: 1 Jul 2040
Completion: 1 Jul 2040
Last update posted: 26 May 2026
Registered enrollment: 200
Registry id: NCT05620771

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.